Duncan Ndegwa Ndungu

Duncan Ndegwa Ndungu

Auto-generated profile, based on publicly available information

Duncan Ndegwa Ndungu

Department of Epidemiology of Microbial Diseases, Yale School of Public Health

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DNDuncan N. Ndegwa
Duncan N. Ndegwa
PKPrasun Kundu
Prasun Kundu
JHJessica B. Hostetler
Jessica B. Hostetler
AMAlejandro Marin-Menendez
Alejandro Marin-Menendez
TSTheo Sanderson
Theo Sanderson
JRJulian C. Rayner
Julian C. Rayner
Plasmodium vivaxis responsible for the majority of malaria cases outside Africa. UnlikeP.falciparum, theP.vivaxlife-cycle includes a dormant liver stage, the hypnozoite, which can cause infection in the absence of mosquito transmission. An effective vaccine againstP.vivaxblood stages would limit symptoms and pathology from such recurrent infections, and therefore could play a critical role in the control of this species. Vaccine development inP.vivax, however, lags considerably behindP.falciparum, which has many identified targets with several having transitioned to Phase II testing. By contrast only oneP.vivaxblood-stage vaccine candidate based on the Duffy Binding Protein (PvDBP), has reached Phase Ia, in large part because the lack of a continuousin vitroculture system forP.vivaxlimits systematic screening of new candidates. We used the close phylogenetic relationship betweenP.vivaxandP.knowlesi, for which anin vitroculture system in human erythrocytes exists, to test the scalability of systematic reverse vaccinology to identify and prioritiseP.vivaxblood-stage targets. A panel ofP.vivaxproteins predicted to function in erythrocyte invasion were expressed as full-length recombinant ectodomains in a mammalian expression system. Eight of these antigens were used to generate polyclonal antibodies, which were screened for their ability to recognize orthologous proteins inP.knowlesi. These antibodies were then tested for inhibition of growth and invasion of both wild typeP.knowlesiand chimericP.knowlesilines modified using CRISPR/Cas9 to exchangeP.knowlesigenes with theirP.vivaxorthologues. Candidates that induced antibodies that inhibited invasion to a similar level as PvDBP were identified, confirming the utility ofP.knowlesias a model forP.vivaxvaccine development and prioritizing antigens for further follow up.

20 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
KMKhadidiatou Mangou
Khadidiatou Mangou
AMAdam J. Moore
Adam J. Moore
LTLaty Gaye Thiam
Laty Gaye Thiam
ABAboubacar Ba
Aboubacar Ba
AOAlessandra Orfanó
Alessandra Orfanó
ABAmy K. Bei
Amy K. Bei
The recent stall in the global reduction of malaria deaths has made the development of a highly effective vaccine essential. A major challenge to developing an efficacious vaccine is the extensive diversity of Plasmodium falciparum antigens. While genetic diversity plays a major role in immune evasion and is a barrier to the development of both natural and vaccine-induced protective immunity, it has been under-prioritized in the evaluation of malaria vaccine candidates. This study uses genomic approaches to evaluate genetic diversity in next generation malaria vaccine candidate PfRh5. We used targeted deep amplicon sequencing to identify non-synonymous Single Nucleotide Polymorphisms (SNPs) in PfRH5 (Reticulocyte-Binding Protein Homologue 5) in 189 P. falciparum positive samples from Southern Senegal and identified 74 novel SNPs. We evaluated the population prevalence of these SNPs as well as the frequency in individual samples and found that only a single SNP, C203Y, was present at every site. Many SNPs were unique to the individual sampled, with over 90% of SNPs being found in just one infected individual. In addition to population prevalence, we assessed individual level SNP frequencies which revealed that some SNPs were dominant (frequency of greater than 25% in a polygenomic sample) whereas most were rare, present at 2% or less of total reads mapped to the reference at the given position. Structural modeling uncovered 3 novel SNPs occurring under epitopes bound by inhibitory monoclonal antibodies, potentially impacting immune evasion, while other SNPs were predicted to impact PfRh5 structure or interactions with the receptor or binding partners. Our data demonstrate that PfRh5 exhibits greater genetic diversity than previously described, with the caveat that most of the uncovered SNPs are at a low overall frequency in the individual and prevalence in the population. The structural studies reveal that novel SNPs could have functional implications on PfRh5 receptor binding, complex formation, or immune evasion, supporting continued efforts to validate PfRh5 as an effective malaria vaccine target and development of a PfRh5 vaccine.

7 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DNDuncan N. Ndegwa
Duncan N. Ndegwa
JHJessica B. Hostetler
Jessica B. Hostetler
AMAlejandro Marin-Menendez
Alejandro Marin-Menendez
TSTheo Sanderson
Theo Sanderson
KMKioko Mwikali
Kioko Mwikali
JRJulian C. Rayner
Julian C. Rayner
Plasmodium vivax is responsible for the majority of malaria cases outside Africa. Unlike P. falciparum , the P. vivax life-cycle includes a dormant liver stage, the hypnozoite, which can cause infection in the absence of mosquito transmission. An effective vaccine against P. vivax blood stages would limit symptoms and pathology from such recurrent infections, and therefore could play a critical role in the control of this species. Vaccine development in P. vivax , however, lags considerably behind P. falciparum , which has many identified targets with several having transitioned to Phase II testing. By contrast only one P. vivax blood-stage vaccine candidate based on the Duffy Binding Protein (PvDBP), has reached Phase Ia, in large part because the lack of a continuous in vitro culture system for P. vivax limits systematic screening of new candidates. We used the close phylogenetic relationship between P. vivax and P. knowlesi , for which an in vitro culture system in human erythrocytes exists, to test the scalability of systematic reverse vaccinology to identify and prioritise P. vivax blood-stage targets. A panel of P. vivax proteins predicted to function in erythrocyte invasion were expressed as full-length recombinant ectodomains in a mammalian expression system. Eight of these antigens were used to generate polyclonal antibodies, which were screened for their ability to recognize orthologous proteins in P. knowlesi . These antibodies were then tested for inhibition of growth and invasion of both wild type P. knowlesi and chimeric P. knowlesi lines modified using CRISPR/Cas9 to exchange P. knowlesi genes with their P. vivax orthologues. Candidates that induced antibodies that inhibited invasion to a similar level as PvDBP were identified, confirming the utility of P. knowlesi as a model for P. vivax vaccine development and prioritizing antigens for further follow up. AUTHOR SUMMARY: Malaria parasites cause disease after invading human red blood cells, implying that a vaccine that interrupts this process could play a significant role in malaria control. Multiple Plasmodium parasite species can cause malaria in humans, and most malaria outside Africa is caused by Plasmodium vivax . There is currently no effective vaccine against the blood stage of any malaria parasite, and progress in P. vivax vaccine development has been particularly hampered because this parasite species cannot be cultured for prolonged periods of time in the lab. We explored whether a related species, P. knowlesi , which can be propagated in human red blood cells in vitro , can be used to screen for potential P. vivax vaccine targets. We raised antibodies against selected P. vivax proteins and testedtheir ability to recognize and prevent P. knowlesi parasites from invading human red blood cells, thereby identifying multiple novel vaccine candidates.

16 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DNDuncan Ndegwa Ndungu
Duncan Ndegwa Ndungu
JTJames Tuju
James Tuju
ECEmily Chepsat
Emily Chepsat
RMRinter Mwai
Rinter Mwai
KMKennedy Mwai
Kennedy Mwai
ABAmy K. Bei
Amy K. Bei
Despite recent progress in the fight against malaria, it still remains a global health challenge necessitating development of intervention strategies. However, the search for malaria vaccine(s) has so far been very challenging. Multiple targets have been tested and so far only a few show promise with one having been endorsed by the WHO. In this study we explore the development of immunity in a low transmission setting, with very few documented re-infections, in order to understand the kinetics of the development and waning of immunity to current and novel blood-stage vaccine candidate antigens. To do this we performed a high-throughput measurement of natural acquired immunity against P. falciparum antigens utilizing a well-established micro-array platform based on the mammalian protein expression system. This large panel of known and novel recombinant full length ectodomain P. falciparum merozoite vaccine candidates were differently recognized by the immune system. Based on the overal spread of the data, some of these antigens induced the acquisition of high levels (1 st tertile) of antibodies, among which included novel antigens such as PF3D7_1025300, PF3D7_1105800, PF3D7_1334400, PF3D7_0911300, PF3D7_1252300, PF3D7_1460600, PF3D7_1453100, PF3D7_0831400 and some induced low levels of antibodies (3rd tertile) while others induced moderate levels (4th tertile). In this longitudinal cohort with low level of malaria endemicity, acquisition of humoral immunity to these full length ectodomains P. falciparum antigens demonstrate different dynamics over-time, whereby it was either not acquired or if it was acquired it was either maintained or lost at different rates. These various identified novel antigens are potentially ideal candidates to be prioritized for further functional and or serological studies.